OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs